© 2005 Oxford University Press
NEWS |
Researchers Exploring Implications of Minimal Residual Cancer
| The first 10% of the full text of this article appears below. |
Klaus Pantel, M.D., Ph.D., director of the Institute of Tumor Biology at the University of Hamburg in Germany, and colleagues started studying minimal residual cancer more than a decade ago when they began seeking an early marker of cancer's systemic spread. Because bone marrow was routinely tested for micrometastases in leukemia and lymphoma patients, Pantel and his colleagues reasoned that the same approach might work for breast cancer.
| |||||||||||
Late this summer, their pooled analysis of more than 4,500 breast cancer patients, which was published in the August 25 New England Journal of Medicine, concluded that "the presence of micrometastasis in the bone marrow at the time of diagnosis of breast cancer is associated with a poor prognosis."
"The old view
Tumor Cells in Peripheral Blood
Tumor Cell Dormancy?
Rare Event Technologies